- Home
- SHMD vs ACET Comparison
SHMD vs ACET Comparison
Compare SHMD & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHMD
- ACET
- Stock Information
- Founded
- SHMD 1864
- ACET 1947
- Country
- SHMD Germany
- ACET United States
- Employees
- SHMD N/A
- ACET N/A
- Industry
- SHMD
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- SHMD
- ACET Health Care
- Exchange
- SHMD Nasdaq
- ACET Nasdaq
- Market Cap
- SHMD 86.1M
- ACET 83.2M
- IPO Year
- SHMD N/A
- ACET N/A
- Fundamental
- Price
- SHMD $2.66
- ACET $0.98
- Analyst Decision
- SHMD
- ACET Buy
- Analyst Count
- SHMD 0
- ACET 5
- Target Price
- SHMD N/A
- ACET $5.67
- AVG Volume (30 Days)
- SHMD 63.1K
- ACET 1.6M
- Earning Date
- SHMD 02-25-2025
- ACET 03-18-2025
- Dividend Yield
- SHMD N/A
- ACET N/A
- EPS Growth
- SHMD 1309.32
- ACET N/A
- EPS
- SHMD 1.07
- ACET N/A
- Revenue
- SHMD $99,752,404.00
- ACET N/A
- Revenue This Year
- SHMD N/A
- ACET N/A
- Revenue Next Year
- SHMD N/A
- ACET N/A
- P/E Ratio
- SHMD $2.90
- ACET N/A
- Revenue Growth
- SHMD N/A
- ACET N/A
- 52 Week Low
- SHMD $1.86
- ACET $0.81
- 52 Week High
- SHMD $6.13
- ACET $2.61
- Technical
- Relative Strength Index (RSI)
- SHMD N/A
- ACET 57.01
- Support Level
- SHMD N/A
- ACET $0.84
- Resistance Level
- SHMD N/A
- ACET $1.04
- Average True Range (ATR)
- SHMD 0.00
- ACET 0.08
- MACD
- SHMD 0.00
- ACET 0.01
- Stochastic Oscillator
- SHMD 0.00
- ACET 68.65
About SHMD SCHMID Group N.V. Class A Ordinary Shares
Schmid Group NV is a global supplier of equipment, software and services for various industries such as printed circuit board (PCB), substrate manufacturing, photovoltaics, and glass and energy storage with a focus on the highest end of this market in terms of technology and performance. It focuses on a modular product portfolio of machinery to use in the manufacturing of high-end PCB equipment and semiconductor packaging devices which includes common flexible circuit fabrication techniques such as subtractive, semi-additive processes (SAP) and modified semi-additive processes (mSAP).
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.